神经妥乐平治疗痛性糖尿病神经病变的疗效分析  

Efficacy of Neurotropin in the Treatment of Painful Diabetic NeuropathyEfficacy of Neurotropin in the Treatment of Painful Diabetic

作　　者：孔凡明 KONG Fanming(Department of Neurology,Yanzhou District Railway Hospital,Jining,Shandong Province,272100 China)

机构地区：[1]济宁市兖州区铁路医院神经内科,山东济宁272100

出　　处：《糖尿病新世界》2023年第8期178-181,共4页Diabetes New World Magazine

摘　　要：目的探究神经妥乐平治疗痛性糖尿病神经病变的疗效。方法选取济宁市兖州区铁路医院2020年1月—2022年6月收治的60例痛性糖尿病周围神经病变(painful diabetic peripheral neuropathy,PDPN)患者作为研究对象。采取随机数表法分为对照组、研究组,每组30例。对照组予以口服卡马西平片治疗,研究组在基础治疗基础上加用神经妥乐平静脉注射治疗。对比两组临床疗效。结果研究组治疗效果、神经传导速度均优于对照组,且TSS评分低于对照组,疼痛缓解时间短于对照组,差异有统计学意义(P<0.05);两组治疗过程中均无明显不良反应发生。结论神经妥乐平治疗DPN疗效确切、安全性较高,可改善患者神经传导速度及疼痛程度、缓解时间。Objective To explore the efficacy of Neurotropin in the treatment of painful diabetic neuropathy.Methods 60 patients with painful diabetic peripheral neuropathy(PDPN)who were admitted to Yanzhou District Railway Hospital from January 2020 to June 2022 are selected as the study objects.Random number table method was used to divide 30 cases into control group and 30 cases into study group.The control group was treated with oral carbamazepine tablets,while the study group was treated with intravenous injection of neurotropin on the basis of basic treatment.The clinical efficacy of the two groups was compared.Results The treatment effect and nerve conduction velocity of the study group were better than those of the control group,and the TSS score was lower than that of the control group,and the pain relief time was shorter than that of the control group,the difference was statistically significant(P<0.05);no obvious adverse reactions occurred in the two groups during the treatment.Conclusion Neurotropin has a definite therapeutic effect and high safety in the treatment of DPN,which can improve the patient's nerve conduction velocity,pain level,and relief time.

关 键 词：神经妥乐平 痛性糖尿病神经病变 疗效 

分 类 号：R587.1[医药卫生—内分泌]